Novel Cause of BPH, PCa Proposed
VIENNA—Benign prostatic hyperplasia (BPH) and prostate cancer could be the result a previously unrecognized route of free testosterone flow from the testes to the prostate, according to investigators.
EAU Congress
Real-Time Elastography Superior for Identifying Prostate Cancer
VIENNA—Real-time elastography has significantly better predictive accuracy for identifying prostate cancer (PCa) lesions compared with contrast-enhanced magnetic resonance imaging (MRI), researchers reported here at the 26th Annual Congress of the European Association of Urology. Biopsy studies need to confirm these results, however.
BoNT-A Efficacy for Idiopathic Detrusor Overactivity Confirmed
VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
Five-Year RARP Outcomes ‘Highly Satisfactory’
VIENNA—Robot-assisted radical prostatectomy (RARP) for localized prostate cancer (PCa) offers “highly satisfactory” five-year oncologic outcomes, according to investigators.
Drug May Be an Alternative to Cystectomy for BCG Failures
VIENNA—Mycobacterial cell wall DNA complex (MCC) may provide an alternative to cystectomy for patients with non-muscle invasive bladder cancer refractory to bacillus Calmette-Guérin (BCG) treatment, according to preliminary study findings.
Testosterone Safe for Prostates
VIENNA—Testosterone replacement therapy benefits hypogonadal men without adversely affecting prostate safety, according to the largest international trial of hypogonadal men receiving the treatment.
Tadalafil Helps Men with Both ED and BPH-LUTS
VIENNA—Tadalafil can improve erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men who suffer from both problems, data suggest.
High-Grade PCa Linked to Metabolic Syndrome
VIENNA—Metabolic syndrome is associated with an increased risk of high-grade prostate cancer (PCa) among men with a positive prostate biopsy, a study found.
CKD Develops in Many Living Kidney Donors
VIENNA—One year after undergoing living donor nephrectomy (LDN), more than half of donors will have chronic kidney disease (CKD), according to a British study. Their decline in renal function, however, appears to remain stable for at least five years and patients rarely suffer adverse cardiovascular events and cardiac mortality.
PSA Screening Lowers Metastasis Risk
VIENNA—PSA screening for prostate cancer (PCa) decreases the risk of PCa-related metastatic disease, according to study findings presented at the European Association of Urology 26th annual congress.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...